Q-omics provides the consensus-scored ADAMTS13 profile across patient tissues and cancer cell-line models. ADAMTS13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADAMTS13 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, ADAMTS13 RNA expression shows 19,365 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where ADAMTS13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS13 survival associations across molecular data types. ADAMTS13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (12) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS13 RNA expression–survival associations across cancer types. High ADAMTS13 expression shows unfavorable associations in KIRC, ACC, COAD and UVM, but favorable associations in SCLC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADAMTS13 RNA expression.
This table summarizes ADAMTS13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ADAMTS13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS13 shows lower tumor expression in LIHC, KIRC, KICH, THCA and CHOL and higher tumor expression in COAD. The LIHC box plot shows higher ADAMTS13 RNA expression in normal versus tumor tissue (log2 FC = −2.476, t-test p < 0.001).
This table shows molecular features associated with ADAMTS13 in patient tissues and cancer cell lines. In patient samples, ADAMTS13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
